HAE צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Haemonetics Company

The quarterly EPS growth rate in the GURU.Markets system is available via a chart, where 22.50 represents the most recent level, allowing users to filter out noise from actual profit dynamics. The defensive nature of the Haemonetics Corporation (HAE) business relies on the constant demand for plasma. Leadership in blood processing ensures high-quality FCF. The expansion of hospital networks effectively scales the sales of high-margin consumables.

Defensive assets are selected based on the stability of their cash flows. Haemonetics Corporation (HAE) confirms this status through high-precision logistics of consumables for blood transfusion centers. An analysis of quarterly EPS growth measures the percentage change in net income per share relative to the previous period. This indicator reveals the actual efficiency of operational capital management. A positive trend confirms the business's resilience to market volatility.